AstraZeneca (AZN) Shares Gap Down to $41.40
AstraZeneca plc (NYSE:AZN)’s share price gapped down prior to trading on Friday . The stock had previously closed at $42.85, but opened at $41.40. AstraZeneca shares last traded at $40.67, with a volume of 7069309 shares changing hands.
A number of equities analysts have recently issued reports on the stock. Deutsche Bank restated a “buy” rating on shares of AstraZeneca in a research note on Monday. HSBC restated a “sell” rating on shares of AstraZeneca in a research note on Monday. ValuEngine upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Saturday, July 28th. Zacks Investment Research upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a research note on Tuesday, October 9th. Finally, Wolfe Research assumed coverage on shares of AstraZeneca in a research note on Tuesday, October 23rd. They issued an “outperform” rating for the company. One investment analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the stock. AstraZeneca currently has an average rating of “Buy” and a consensus target price of $40.34.
The company has a debt-to-equity ratio of 1.36, a quick ratio of 0.66 and a current ratio of 0.86. The firm has a market capitalization of $105.09 billion, a price-to-earnings ratio of 9.50, a PEG ratio of 2.13 and a beta of 0.57.
In other news, major shareholder Plc Astrazeneca bought 600,000 shares of the stock in a transaction dated Monday, October 22nd. The shares were acquired at an average price of $5.00 per share, with a total value of $3,000,000.00. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Several institutional investors and hedge funds have recently bought and sold shares of the company. TIAA CREF Investment Management LLC grew its holdings in shares of AstraZeneca by 66.4% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 819,329 shares of the company’s stock worth $32,421,000 after purchasing an additional 326,817 shares during the last quarter. Teachers Advisors LLC grew its holdings in shares of AstraZeneca by 12.2% in the 3rd quarter. Teachers Advisors LLC now owns 1,043,073 shares of the company’s stock worth $41,274,000 after purchasing an additional 113,265 shares during the last quarter. Neuberger Berman Group LLC grew its holdings in AstraZeneca by 174.2% during the 3rd quarter. Neuberger Berman Group LLC now owns 527,906 shares of the company’s stock worth $20,890,000 after acquiring an additional 335,355 shares during the last quarter. Henry James International Management Inc. bought a new stake in AstraZeneca during the 3rd quarter worth about $455,000. Finally, Mackenzie Financial Corp grew its holdings in AstraZeneca by 8.2% during the 3rd quarter. Mackenzie Financial Corp now owns 29,680 shares of the company’s stock worth $1,174,000 after acquiring an additional 2,247 shares during the last quarter. 16.03% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “AstraZeneca (AZN) Shares Gap Down to $41.40” was published by Daily Political and is the property of of Daily Political. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2018/11/16/astrazeneca-azn-shares-gap-down-to-41-40.html.
AstraZeneca Company Profile (NYSE:AZN)
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.